Table 5: Reasons why clinicians reported ordering specific cancer genomics tests in the past 12 months, among clinicians who ordered the genetic tests.

Patient met practice guidelines
  (%)a     
(95%  CI)b
Guide future screening decisions
  (%)a     
(95%  CI)b
Guide prophylactic treatment decisions
  (%)a     
(95%  CI)b
Patient specifically requests it
  (%)a     
(95%  CI)b

BRCA for patients without BCc or OCd,e207 (85.5%)192 (79.7%)192 (79.7%)198 (81.1%)
(80.5%–89.5%)(74.1%–84.3%)(74.1%–84.3%) (75.7%–85.6%)

BRCA for patients with BCc or OCd,f100 (82.0%)91 (75.2%)93 (76.2%)97 (78.9%)
(74.0%–87.9%)(66.6%–82.2%)(67.8%–83.0%)(70.6%–85.3%)

Lynch syndrome testingg for patients w/o CRCh,i72 (63.7%)69 (60.5%)68 (58.6%)65 (57.0%)
(54.3%–72.2%)(51.2%–69.2%)(49.3%–67.3%)(47.7%–65.9%)

Lynch syndrome testingg for patients with CRCh,j50 (72.5%)46 (67.6%)27 (40.3%)32 (50.0%)
(60.5%–81.9)(55.4%–77.9%) (29.0%–52.7%)k(37.7%–62.3%)

aThe column % reflects the percent responding within each practice category.
bCI: confidence interval.
cBC: breast cancer.
dOC: ovarian cancer.
eAmong clinicians who recommend breast and ovarian screening to patients without breast cancer.
fAmong clinicians who treat breast and ovarian cancer.
gSpecifically testing for mismatch repair (MMR) genes, which may include testing in MCH1, MSH2, MSH6, and PMS2 genes.
hCRC: colorectal cancer.
iAmong clinicians who recommend colorectal cancer screening to patients without colorectal cancer.
jAmong clinicians who treat colorectal cancer.
kFor Lynch syndrome testing for patients with cancer, the phrasing was “guide chemotherapeutic treatment decisions.”